文献速递炎症性肠病

TIM3信号在效应T细胞中作为嘌呤降解通路的免疫代谢开关抑制肠道炎症

TIM3 Signaling in Effector T Cells Acts as an Immunometabolic Switch in the Purine Degradation Pathway to Suppress Intestinal Inflammation.
PubMed 文献 · Gastroenterology · 2026-06-17

本研究结合TIM3缺陷小鼠实验性结肠炎模型与人IBD样本分析,发现IBD患者血液Th1和黏膜Th17细胞TIM3表达升高,且在抗TNF难治患者中尤其高。TIM3信号通过抑制ADA和嘌呤降解通路,使效应T细胞保持在耗竭的PD1+状态,从而发挥免疫代谢调节作用。Gal-9治疗可通过ADA抑制改善实验性结肠炎。

要点

  • IBD患者Th1和Th17细胞TIM3表达升高,抗TNF难治者尤其高
  • TIM3信号抑制ADA和嘌呤降解通路,维持效应T细胞耗竭状态
  • Gal-9通过ADA抑制改善实验性结肠炎,诱导免疫代谢转换

核心结论

  • TIM3通过抑制ADA和嘌呤降解通路调控效应T细胞免疫代谢,在结肠炎中起关键作用。
  • 靶向TIM3激活效应T细胞的免疫代谢功能是慢性肠道炎症的潜在策略。

研究设计与样本

  • 结合TIM3缺陷小鼠实验性结肠炎模型与人IBD及对照样本分析。
  • 采用多色流式细胞术、细胞因子谱分析和非靶向代谢组学评估血液和黏膜T细胞。
  • 分析单细胞测序数据,并使用TIM3配体Gal-9研究TIM3功能。

主要发现

  • IBD患者血液Th1和黏膜Th17细胞TIM3表达高于对照,抗TNF难治患者中尤其高。
  • TIM3缺陷小鼠奥唑酮结肠炎加重,效应T细胞活化增加。
  • TIM3信号抑制ADA和嘌呤降解通路,使效应T细胞保持在耗竭的PD1+状态。
  • 慢性炎症中Gal-9可用性不足限制有效TIM3信号。
  • Gal-9治疗通过ADA抑制改善实验性结肠炎,并在IBD T细胞中诱导与终末耗竭Th17细胞减少相关的免疫代谢转换。

临床怎么用

  • TIM3表达水平可能有助于识别抗TNF难治的IBD患者。
  • 激活TIM3信号或补充Gal-9可能成为慢性肠道炎症的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Effector T lymphocytes have been found to play a key role in inflammatory bowel diseases (IBDs). However, the molecular pathways controlling their metabolism and functional activity remain poorly defined. We aimed to elucidate the role of the immune checkpoint receptor TIM3 for T-cell signaling in IBDs. METHODS: We combined experimental colitis models in TIM3-deficient mice with analyses of human IBDs and control samples. Blood and mucosal T cells were assessed using multicolor flow cytometry, cytokine profiling, and untargeted metabolomics. Single-cell sequencing data were analyzed. The TIM3 ligand Gal-9 was used to study TIM3 function. RESULTS: TIM3 expression was higher on blood T-helper cells (Th) type 1 and mucosal Th17 cells in patients with IBD compared with controls, with levels being particularly high in anti-TNF refractory patients. Mice lacking TIM3 showed exacerbated oxazolone colitis and increased effector T-cell activation. Metabolome profiling and functional analyses revealed that TIM3 signaling functions as an immunometabolic regulator, suppressing ADA and the purine degradation pathway to keep effector T cells in an exhausted PD1+ state. However, insufficient availability of the TIM3 ligand Gal-9 limited effective TIM3 signaling in chronic inflammation. Treatment with Gal-9 ameliorated experimental colitis via ADA inhibition. Moreover, in IBD T cells, Gal-9 induced an immunometabolic switch associated with reduction of terminally exhausted Th17 cells. CONCLUSIONS: TIM3 plays a key role in the immunometabolism of effector T cells in colitis by suppressing ADA and the purine degradation pathway. Targeting the immunometabolic functions of effector T cells via TIM3 activation emerges as a promising strategy for chronic intestinal inflammation.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Knauss A, Gabel M, Kaufmann C, et al. TIM3 Signaling in Effector T Cells Acts as an Immunometabolic Switch in the Purine Degradation Pathway to Suppress Intestinal Inflammation. Gastroenterology. 2026. PMID: 42309263. doi:10.1053/j.gastro.2026.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。